DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019


MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq:DMAC) today announced that it will be attending the 31st Annual ROTH ConferenceMarch 18-19, 2019, at The Ritz Carlton, Laguna Niguel in Dana Point, CA. DiaMedica's President and CEO, Rick Pauls, will be hosting one-on-one meetings with institutional investors at the conference and attendees can contact their Roth Capital Partners representative to arrange a meeting.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. The Company currently has an ongoing phase II study in acute ischemic stroke and a phase Ib study in chronic kidney disease. DiaMedica's shares are listed on The Nasdaq Capital Market under the trading symbol "DMAC."

For more information, please visit www.diamedica.com.


Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118


Paul Papi

Vice President of Business Development

Phone: (617) 899-5941


Source: DiaMedica Therapeutics Inc.

In This Story